Information über den neuen RSV-Impfstoff NIRSEVIMAB / Information about the new RSV vaccine NIRSEVIMAB

Information über den neuen RSV-Impfstoff NIRSEVIMAB

Das Respiratorische-Synzytial-Virus (RSV) ist ein «Erkältungsvirus», das bei Säuglingen eine Bronchiolitis (Entzündung der kleinsten Atemwege) verursachen kann. Ein Teil dieser Säuglinge muss als Folge davon wegen Atemnot, Trinkschwäche und Sauerstoffbedarf im Spital behandelt werden, ein kleiner Teil davon auf der Intensivstation.

Seit Dezember 2023 ist ein neuer RSV-Impfstoff (Nirsevimab) vom Schweizerischen Heilmittelinstitut zugelassen. Es handelt sich um eine einmalige Dosis ab sofort.

Studien haben gezeigt, dass damit die RSV-bedingten Spitalaufenthalte von Säuglingen um 70-90% gesenkt werden konnten. Routinemässig wurde der Impfstoff bereits in Winterhalbjahr 2023/2024 in den USA, Frankreich, Spanien und Luxemburg angewendet.

Am 1. September 2024 ist Nirsevimab in die Spezialitätenliste aufgenommen worden, das bedeutet, die Krankenkassen übernehmen die Kosten von knapp CHF 400.-.

Nirsevimab kann in Kinderarztpraxen und Spitalambulatorien allen Säuglingen verabreicht werden, die ab April 2024 geboren wurden.

Das Produkt ist jetzt verfügbar. Unsere Stammpatientinnen und Stammpatienten können sich für einen Termin gerne telefonisch bei uns melden. Zudem übernehmen wir einmalig auch Impfungen für weitere Kinder (sofern Ihr Kinderarzt/Ihre Kinderärztin keinen Termin/keinen Impfstoff anbieten kann).

Ihr Swiss Medi Kids Team

 

 

Information about the new RSV vaccine NIRSEVIMAB

The respiratory syncytial virus (RSV) is a “cold virus” that can cause bronchiolitis (inflammation of the smallest airways) in infants. As a result, some babies need to be treated at a hospital due to respiratory distress, feeding difficulties and need for oxygen. A a small number of them require intensive care.

A new RSV vaccine (nirsevimab) has been approved by the Swiss Agency for Therapeutic Products since December 2023. This is a single dose vaccine.

Studies have shown that RSV-related hospitalizations of infants can be reduced up to 70-90%. The vaccine was widely used during the 2023/2024 winter in the USA, France, Spain and Luxembourg.

On September 1, 2024, nirsevimab was added to the Swiss list of specialties, which means that health insurance companies will cover the costs of just under CHF 400.

Nirsevimab is recommended for all infants born since April 2024 and can be administered at pediatric practices and outpatient clinics.

The product is now available. Our regular patients are welcome to call us for an appointment. We also provide vaccinations for other infants (if your pediatrician is unable to offer an appointment/a vaccine).

Your Swiss Medi Kids Team

Swiss Medi Kids Wertebilder 2
Swiss Medi Kids Wertebilder 1

We care for your child - every day

Swiss Medi Kids is the largest children’s Permanence in Switzerland and treats children and adolescents up to the age of 16 every day until 8 p.m. at the Zurich, Winterthur and Lucerne locations. Please note that only 1 accompanying person is allowed per walk-in patient. Of course, both parents are allowed to come along for check-ups.

Walk-ins

All families with children can come to us as walk-ins, regardless of whether they have their own pediatrician or not. We will then inform the pediatrician of this visit so that the medical history remains complete. In the event of an extremely high volume of patients, we reserve the right to treat only absolutely urgent cases and to refer all other cases to other competent services.

Regular patients

We accept new regular patients at all locations. Please contact us at admin@swissmedikids.ch.

Please note that the Bexsero vaccine (meningococcal B vaccine) is available at the moment. Please contact us.

Video and telephone consultations

We offer video and telephone consultations with our pediatric team. You can find more information here.

More about us

Innovation for good

Swiss Medi Kids is fighting for fair rates in the evenings and at weekends following two federal court rulings. Because at Swiss Medi Kids, 50% of 80,000 consultations take place in the evening after 5 p.m. and on weekends and public holidays. Because children don’t only fall ill during office hours. A solution is now emerging: We are intensifying our cooperation with Swica and CSS with managed care contracts in order to secure our existence. We are currently working hard to ensure that all insurers follow the innovative example set by these two health insurers.

Nothing will change for our patients for the time being. We will continue to treat ALL patients 365 days a year until 8 pm. And we will do our best to ensure that this remains as it is.

The full press release can be viewed here.

The following insurers already work with us on managed care contracts:

Concordia

CSS

Swica

Helsana

KPT

Sanitas

We are very proud that our minister of health, Elisabeth Baume – Schneider supports us in her interview with Blick on October 28, 2024.